Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Autus Valve Early Feasibility Study

15. oktober 2026 oppdatert av: Edwards Lifesciences

Autus størrelsesjusterbar ventil for kirurgisk lungeventilerstatning tidlig mulighetsstudie

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Faktiske)

62

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Ann and Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan - Mott Children's Hospital
    • New York
      • New York, New York, Forente stater, 10032
        • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
    • North Carolina
      • Durham, North Carolina, Forente stater, 27703
        • Duke University
    • Ohio
      • Columbus, Ohio, Forente stater, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City, Utah, Forente stater, 84113
        • University of Utah - Intermountain Primary Children's Hospital
    • Washington
      • Seattle, Washington, Forente stater, 98105
        • Seattle Children's Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år til 16 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.

  1. Age 18 months to 16 years.

  2. Male or female.

  3. Subject has a native or repaired right ventricular outflow tract.

  4. Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).

  5. Subject has at least one of the following echocardiographic findings:

    1. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
    2. Moderate or greater pulmonary regurgitation;
    3. Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
  6. Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).

  7. Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.

  8. Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are met:

  1. Subject requires valve replacement in a non-pulmonary position.
  2. Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
  3. Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
  4. Subject has pulmonary atresia and major aortopulmonary collaterals.
  5. Subject has significant peripheral pulmonary artery stenosis.
  6. Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
  7. Subject has active endocarditis or a history of infective endocarditis.
  8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
  9. Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
  11. Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
  12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
  13. Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
  14. Subject needs emergency cardiac or vascular surgery or intervention.
  15. Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
  16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
  17. Subject or parent/legal representative refuses blood transfusions.
  18. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
  19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Autus Valve Arm

Pulmonary Valve Replacement Surgery with the Autus Valve

Pulmonary valve replacement surgery with the Autus Valve

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Valve Implantation Primary Safety Endpoint
Tidsramme: 30 Days post-valve implantation

Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
30 Days post-valve implantation
Valve Implantation Primary Effectiveness Endpoint
Tidsramme: 6 Months post-valve implantation

Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:

  • A mean RVOT gradient less than or equal to 40 mmHg and
  • Less than moderate pulmonary regurgitation by transthoracic echo and
  • No Autus Valve reintervention except for valve expansion to address prosthesis-patient mismatch.
6 Months post-valve implantation

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Other Safety Outcome - Composite
Tidsramme: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Mortality
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Mortality, including: all cause, cardiac-related, procedure-related and device-related

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve Thrombosis
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Valve thrombosis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Thromboembolism
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Thromboembolism

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Cardiac or Valve Intervention
Tidsramme: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Other cardiac or valve intervention (surgical or transcatheter)

30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
Other Safety Outcome - Major Hemorrhage
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Major hemorrhage

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Endocarditis
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Endocarditis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Hemolysis
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Hemolysis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Device Explantation
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Device explantation

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Adverse Events (AE)
Tidsramme: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Adverse events

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve/Stent Fracture
Tidsramme: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.

An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure.

pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Tidsramme: Immediately Post-Valve Implant Procedure

To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):

  • RV to PA peak systolic pressure gradient <40 mmHg (direct pressure measurement);
  • None or trivial pulmonary regurgitation (assessed via TEE);
  • No paravalvular leak (assessed via TEE).
Immediately Post-Valve Implant Procedure
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Right Ventricular Measures
Tidsramme: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Left Ventricular Measures
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Modified Ross Functional Classification
Tidsramme: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Modified Ross Functional Class as assessed by the Site Investigators

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - PedsQL - Cardiac Module
Tidsramme: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.

The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel.

Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
Other Post-Implant Valve Expansion Safety Outcome - Composite
Tidsramme: 30 days after each post-implant valve expansion procedure

Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:

  • Death;
  • Extracorporeal membrane oxygenation (ECMO) support;
  • Unplanned intervention (surgical or transcatheter);
  • Major hemorrhage
30 days after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Tidsramme: Immediately after each post-implant valve expansion procedure

To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:

  • RV to aortic systolic pressure ratio: ≤0.5.
  • Peak-to-peak RV to PA systolic pressure gradient: ≤15 mmHg;
  • Peak-to-peak RV to PA systolic pressure gradient: ≥50% reduction (pre vs post valve expansion).
Immediately after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Tidsramme: 6 months after each post-implant valve expansion procedure

Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:

  • Less than moderate pulmonary regurgitation (PR) by Doppler echocardiography;
  • Transvalvular gradient (assessed by CW Doppler) at 6-months is lower than the pre-expansion gradient.
6 months after each post-implant valve expansion procedure

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. februar 2024

Primær fullføring (Faktiske)

24. august 2026

Studiet fullført (Antatt)

5. februar 2036

Datoer for studieregistrering

Først innsendt

23. juli 2021

Først innsendt som oppfylte QC-kriteriene

12. august 2021

Først lagt ut (Faktiske)

16. august 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere